[3P] 70 Neurodegenerative Disorders

[3P-332] BDNF Val66Met Polymorphism as a Potential Biomarker for Predicting Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patient

Presentation at Industrial-Academic Collaboration

*LI-Hsien Chen¹, Peng-Chan Lin^2,3, Yu-Min Yeh², Jang-Yang Chang^4,5,6, Meng-Ru Shen^1,7,8 (1. Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 2. Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan., 3. Department of Genomic Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan., 4. Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, 5. Taipei Cancer Center, Taipei Medical University Hospital, Taipei 110, Taiwan , 6. TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 110, Taiwan, 7. Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 8. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan)

Keywords:Chemotherapy-induced peripheral neuropathy, BDNF, Val66Met single-nucleotide polymorphism, Colorectal Cancer